'Prevent death' message more effective than 'save life' in blood donation campaigns

Subtle changes in messaging can have a profound impact on the effectiveness of charitable messages such as calls for blood donations, according to research published March 6 in the open access journal PLOS ONE by Eileen Chou from the University of Virginia and co-author Keith Murnighan at Northwestern University.

Though chronic shortages in U.S blood banks could be alleviated by a small increase in the number of , people are not always motivated enough to help. In the current study, researchers collaborated with the Red Cross to assess the effects of changing the urgency and messaging of a call for . The scientists found that on a college campus, describing blood donations as a way to "prevent a death" rather than "save a life" significantly increased the rate of donations.

In a second study, the researchers assessed the effects of these slight changes in framing a charitable message on people's emotional motivation for a . Here, they found that framing an appeal as "helping people to avoid a loss" rather than "helping people to gain benefits" led to increased intentions to volunteer and more helping behavior. Volunteers presented with such "prevention of loss" messages were also more likely to expect larger donations to their cause. "These findings demonstrated a simple, reliable, and effective method for charities to significantly increase important helping behaviors," Chou said.

More information: Chou EY, Murnighan JK (2013) Life or Death Decisions: Framing the Call for Help. PLOS ONE 8(3): e57351. doi:10.1371/journal.pone.0057351

add to favorites email to friend print save as pdf

Related Stories

Cause marketing lowers charitable donations

Mar 31, 2011

(PhysOrg.com) -- Cause marketing -- when firms share proceeds from the sale of products with a social cause -- reduces charitable giving by consumers, says a researcher at the University of Michigan's Ross School of Business. ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

23 hours ago

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments